MiniMed® 640G System

BREAKTHROUGH TECHNOLOGY THAT THINKS ABOUT YOUR PATIENTS’ GLUCOSE CONTROL
Insulin pump therapy is an effective way to provide your patients with better control and outcomes.¹ Both lead to higher patient satisfaction and adherence to treatment plans.²

By recommending insulin pump therapy to your patients, you could see a significant improvement in their HbA1c and a reduced occurrence of long-term complications.

Insulin Pump Therapy has been shown to enable reductions in HbA1c of 0.9% when compared to MDI.¹ The STAR 3 study has further demonstrated the additional benefit of using sensor augmented pump therapy to further reduce HbA1c.

In this study the average reduction in HbA1c was 1.2% in the participants who used CGM for more than 80% of the time as compared to MDI patients.³

Insulin pump therapy patients are **four times** more likely to achieve their HbA1c goals compared to those on MDI.¹

Your patients can experience a decreased risk of long-term complications:⁴

- **Cardiovascular damage:** Reduced up to 41%
- **Nerve damage (neuropathy):** Reduced up to 60%
- **Kidney damage:** Reduced up to 54%
- **Eye damage (retinopathy):** Reduced up to 63%
You think about helping your patients achieve better glucose control. Their **system** should, too.

You want your patients to achieve tight glucose control and avoid hypoglycaemia. What if you could prescribe an insulin pump system that could help them do just that?

The MiniMed® 640G System^ features exclusive SmartGuard™ technology that actually thinks* about your patients’ diabetes and helps them follow your prescribed therapy plan.

**MiniMed® 640G System^**

The unique **MiniMed®** connection offers secure insulin delivery, with an infusion set for every lifestyle.

Our enhanced **Enlite™ sensor and new Guardian™ 2 Link transmitter** allow continuous monitoring of glucose levels with greater performance and comfort.^7

The exclusive and simple to use blood glucose meter **Contour® Next LINK 2.4** from Bayer links wirelessly to the MiniMed® 640G, providing accurate testing with Multipulse™ technology, and discreet remote bolusing.

**Medtronic CareLink®** software includes easy-to-interpret trend reports and useful therapy considerations to support treatment optimisation.
MiniMed® 640G is our most advanced diabetes management system available with SmartGuard™ technology.

MiniMed® 640G combines the intelligence of SmartGuard™ with the performance of Enlite™ to help mimic more of the functions of a healthy pancreas. The result is an integrated technology that helps you and your patients manage highs and lows.

**CONTINUOUS GLUCOSE MONITORING (CGM)**

Integrated CGM makes diabetes management more informative for you and more actionable for your patients.9

With Guardian™ 2 Link and Enlite™ sensor, your patients can:

- Accurately and continuously monitor glucose levels
- Comfortably wear the sensor for up to six days
- Be alerted before sensor glucose is above or below user-set limits

**ADVANCED PROTECTION WITH SMARTGUARD™**

The goal of the latest SmartGuard™ advancement was to optimise the system’s ability to help patients:

- Prevent severe hypoglycaemic episodes by automatically stopping insulin when sensor glucose is predicted to approach a low limit13
- Avoid hyperglycaemic rebound, resuming insulin delivery when levels recover14
- Better protect against lows throughout the day and night with multiple limit settings
- Dynamically stopping insulin delivery reduces the length and severity of low glucose levels15,16

98% Enlite™ detected 98 percent of hypoglycaemic events.1,11

93 percent of those who used a suspend feature in their pump felt more secure managing their diabetes.17

8 out of 10 who used Enlite™ with their insulin pump felt more confident in managing highs and lows.7

4 out of 10 users reported not feeling the Enlite™ sensor under their skin at all.2

CGM identifies up to four times as many serious glucose excursions as compared to self-monitoring with a blood glucose meter.10

8 out of 10 who used Enlite™ with their insulin pump felt more confident in managing highs and lows.7
How SmartGuard™ works in the MiniMed® 640G
(for illustration purposes only)

SmartGuard™ suspends basal insulin delivery because sensor glucose is predicted to be approaching the preset low limit in 30 minutes.¹³

Basal insulin delivery automatically resumes because sensor glucose is above the preset low limit and trending upwards.¹⁴

IMPORTANT:
Your patient may also manually resume insulin delivery at any time.
Diabetes is already complicated. What you prescribe shouldn’t be.

MiniMed® 640G was inspired by years of feedback from patients and healthcare professionals like you, who want technology to be smart — and easy to use.

**GREATER CONVENIENCE**

- **MORE INFORMATIVE BOLUS WIZARD™ CALCULATOR**
- **PROGRAMMABLE TREATMENT REMINDERS**
- **REMOTE BOLUS FROM METER**
- **SIMPLE-TO-SET PRESET BOLUS AND BASAL PATTERNS**
- **LOUDER, VOLUME-ADJUSTABLE ALERTS**

**Intuitive to Learn**

MiniMed® 640G has an intuitive interface that helps your patients learn and follow the therapy plans you prescribe. In a recent study, on average, those who were trained on the MiniMed® 640G pump:

- Found it very intuitive
- Felt confident using the pump
- Found it easy to access critical information and perform common tasks
MINIMED® 640G SYSTEM®

**IMPROVED DESIGN**

- **WATERPROOF AT 3.6 METRES FOR UP TO 24 HOURS (IPX8)**
- **FULL-COLOUR, AUTO-BRIGHTNESS DISPLAY**
- **INTUITIVE SCREEN NAVIGATION**
- **ERGONOMIC DESIGN FOR RIGHT- AND LEFT-HANDED USERS**

MiniMed® 640G is available in five accent colours.

<table>
<thead>
<tr>
<th>Colour</th>
<th>Colour</th>
<th>Colour</th>
<th>Colour</th>
<th>Colour</th>
</tr>
</thead>
<tbody>
<tr>
<td>black</td>
<td>grey</td>
<td>blue</td>
<td>purple</td>
<td>pink</td>
</tr>
</tbody>
</table>

**Give your patients technology that thinks.**

Contact your Medtronic representative to learn more about MiniMed® 640G, technology that thinks about your patients’ glucose control.
**CONTOUR® NEXT LINK 2.4 from Bayer — the only meter that links to the MiniMed® 640G System^ to help your patients achieve better glucose control.**

**BETTER OUTCOMES FOR PATIENTS**

The **CONTOUR® NEXT LINK 2.4** meter uses the **CONTOUR® NEXT** test strip, the newest strip technology from Bayer, to provide your patients with accuracy and performance.

**No Coding™ Technology**
Removes the need for patients to code the meter manually, preventing miscoding errors that could produce inaccurate results (by as much as 4.0 mmol/L).²³

**Multipulse™ Accuracy Technology**
Ensures more accurate glucose measurements, even when blood glucose levels are low vs. **CONTOUR® LINK**. Provides accuracy unaffected by many common interfering substances and medications.²⁴

**CONTOUR® NEXT test strips**
Provides accurate blood glucose readings for your patients. Exceeds ISO 15197:2013 minimum accuracy requirements in the lab.²⁵,²⁶

---

**Percentage of accurate results with the CONTOUR® NEXT LINK 2.4 meter system²⁵,²⁶**

<table>
<thead>
<tr>
<th>ISO Standard</th>
<th>&lt; 5.6 mmol/L Within ±0.83 mmol/L</th>
<th>&gt; 5.6 mmol/L Within ±10%</th>
<th>&lt; 5.6 mmol/L Within ±0.83 mmol/L</th>
<th>&gt; 5.6 mmol/L Within ±15%</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013 (section 6:3)</td>
<td>98.4%</td>
<td>99.3%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>2013 (section 6:3)</td>
<td>Parkes-Consensus Error Grid results: 100% of the results fall within zone A (having no effect on clinical action)²³,²⁵,²⁶</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

²² Parkes-Consensus Error Grid results: 100% of the results fall within zone A (having no effect on clinical action)²³,²⁵,²⁶
EASY MANAGEMENT FOR PATIENTS

The Contour® Next LINK 2.4 meter wirelessly connects to the MiniMed® 640G System® and provides your patients added convenience to manage their diabetes effectively.

Remote Bolusing
Seamlessly connects to MiniMed® 640G and discreetly sends bolus commands to the pump.

Automatic Transfer
Automatically sends blood glucose values to the Bolus Wizard™ feature on MiniMed® 640G, helping to ensure easier bolus dosing.

Easier Sampling
Features Sip-In Sampling™ technology that automatically draws blood into the test chamber. Offers Second-Chance™ sampling that allows patients to add more blood if initial samples are insufficient.

SMARTER TRACKING

The Contour® Next LINK 2.4 meter connects to Medtronic CareLink® therapy management software, allowing your patients to track their blood glucose control in greater detail.

Medtronic CareLink® upload
Conveniently allows your patients to upload both their meter and pump information to Medtronic CareLink® software, which provides you with detailed logs to optimise therapy adjustments.

- Has been shown to help reduce HbA1c among users,\(^2\) which can lead to reductions in complications
- Detailed, easy-to-interpret glucose trend reports conveniently allow you to review patient events and trends
CareLink® Overview

CARELINK® PERSONAL

- Convenient online tool that brings together critical information from diabetes monitoring devices:
  - Medtronic insulin pump
  - Continuous glucose monitoring system
  - Blood glucose meter

- Serves as a virtual logbook so your patients can accurately track insulin intake and glucose levels, making it easier to compare any changes in glucose levels with daily activities, such as meals and exercise routines.

- Charts and graphs allow you to see the changes visually, while tables provide the actual numeric values.

CARELINK® PROFESSIONAL

CareLink® Pro is a diabetes therapy management software for a personal computer (PC):

- Allows you to acquire, store, and report patient treatment and diagnostic data.

- You can also use it to access pump, meter, and sensor-based glucose data your patients have uploaded to CareLink® Personal.

- CareLink® Pro interfaces with the CareLink® Personal system, allowing access to device data patients have stored there. This is ideal for creating current reports between office visits, and may make the need to read device data during office visits unnecessary.
# CARELINK® PROFESSIONAL REPORTS

<table>
<thead>
<tr>
<th><strong>Visual</strong></th>
<th><strong>Description</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Image" /></td>
<td><strong>1. Adherence Report</strong>&lt;br&gt;Enables targeted patient conversations for faster resolution of care</td>
</tr>
<tr>
<td><img src="image2.png" alt="Image" /></td>
<td><strong>2. Log Book</strong>&lt;br&gt;Visual glycaemic profile for quick reference</td>
</tr>
<tr>
<td><img src="image3.png" alt="Image" /></td>
<td><strong>3. Sensor and Meter Overlay</strong>&lt;br&gt;Joins the dots in faster time period</td>
</tr>
<tr>
<td><img src="image4.png" alt="Image" /></td>
<td><strong>4. Device Settings</strong>&lt;br&gt;A baseline reference – dynamic with each download</td>
</tr>
<tr>
<td><img src="image5.png" alt="Image" /></td>
<td><strong>5. Daily Detail</strong>&lt;br&gt;Reports on a daily basis to explain the ‘WHY’</td>
</tr>
<tr>
<td><img src="image6.png" alt="Image" /></td>
<td><strong>6. Therapy Dashboard</strong>&lt;br&gt;‘ONE STOP SHOP’ linking all aspects of insulin effect on glucose profile</td>
</tr>
<tr>
<td><img src="image7.png" alt="Image" /></td>
<td><strong>7. Episode Summary</strong>&lt;br&gt;Provides suggestions for prioritised fine tuning</td>
</tr>
</tbody>
</table>
MiniMed® 640G System

it thinks

with SmartGuard™

MiniMed® 640G System

References:
1. Components sold separately. Automated insulin delivery is made possible through combining Medtronic insulin pump and continuous glucose monitoring technology. Within 30 minutes of event, both Low Glucose Limit and Low Predictive alert ON with 31.0 percent false alert rate, calibrating 3-4 times daily. 
6. MiniMed® 640G with Enlite™ has a MARD of 14.2 percent. (SmartGuard Sensor Performance Report) when calibrated 3-4 times daily. 
8. Compared to basic integrated system technology with insulin pump and CGM. 
9. Compared to non- CGM CSII or separate CGM technology not integrated with the insulin delivery pump system. 
12. The SmartGuard™ algorithm optimisation was based on the unique characteristics of how the Medtronic devices function as an integrated system. The true efficacy of the algorithm in preventing hypoglycaemia and hyperglycaemia has not yet been validated through direct clinical evidence. 
13. The dynamic suspend feature is based on certain criteria: sensor glucose must be within ±0.9 mmol/L above the preset low limit and predicted to be no more than 1.1 mmol/L above the low limit within 30 minutes AND the pump must not be in the refractory period. 
14. The dynamic resume feature is based on certain preset criteria: sensor glucose must be at least 11 mmol/L above the preset low limit and predicted to be greater than 2.2 mmol/L above within 30 minutes AND insulin must have been suspended for at least 30 minutes. 
20. Compared to Medtronic MiniMed® Paradigm™ Veo™ system. 
21. Calculation is based on the amount of insulin currently in the body, the amount of carbohydrates, the user's current and target blood sugar levels, their insulin-to-carb ratio and their body's sensitivity to insulin. Proper bolus Wizard™ setup must be completed first. 
22. At times of manufacture up to 1.6 metres for up to 24 hours at a time. 
26. Bayer Healthcare LLC. 
27. International Organization for Standardization. 
30. See Contraindication for list of contraindications. 
32. Bayer Healthcare LLC. 
33. Safety Information: MiniMed® 640G Insulin Pump is indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. In addition, the Enlite glucose sensor is intended for continuous or periodic monitoring of glucose levels in the fluid under the skin, and possible low and high blood glucose episodes. 
34. Pump history can be downloaded to a computer for analysis of historical glucose values. The continuous glucose values provided by the MiniMed® 640G insulin pump are not intended to be used directly for making therapy adjustments. Rather, they provide an indication that a confirmation fingerstick measurement may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not based on the value displayed by the pump. 
35. Safety Information: Medtronic CareLink™ software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into Medtronic CareLink™ reports that can be used to identify trends and track daily activities—such as carbohydrates consumed, meal times, insulin delivery and glucose readings. Medtronic CareLink™ report data is intended for use as an adjunct in the management of diabetes only and NOT intended to be relied upon by itself. 
36. MiniMed and Medtronic CareLink are registered trademarks and SmartGuard, Guardian, Enlite, Bolus Wizard, Paradigm and Veo are trademarks of Medtronic MiniMed, Inc. Bayer, the Bayer Cross and CONTOUR are registered trademarks and Sin-p Sampling, No Coding, Multipulse and Second Chance are trademarks of Bayer Healthcare, LLC.